We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK, Vir Begin Phase 2/3 Trial of COVID-19 Antibody Treatment
GSK, Vir Begin Phase 2/3 Trial of COVID-19 Antibody Treatment
GlaxoSmithKline and Vir Biotechnology have dosed the first patient in a phase 2/3 clinical trial of their investigational COVID-19 antibody treatment VIR-7831 for early treatment in patients at high risk of hospitalization.